Drugs / Benzbromarone

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT02317861 Dec 2014 → Jun 2015 gout AstraZeneca Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02790450 Oct 2015 → Aug 2016 idiopathic pulmonary arterial hypertension Medical University of Graz Completed No outcome recorded
Phase 42 trials
Phase 4 NCT05210517 Oct 2020 → Jun 2021 type 2 diabetes mellitus Amsterdam UMC, location VUmc Completed No outcome recorded
Phase 4 NCT00422318 Jan 2004 → Dec 2005 heart failure Tottori University Hospital Completed No outcome recorded
Phase not applicable2 trials
NCT02944214 Oct 2016 → Dec 2019 chronic kidney disease, impaired renal function disease Shanghai 10th People's Hospital Unknown No outcome recorded
NCT02338323 Jan 2015 → Dec 2018 chronic kidney disease, impaired renal function disease Shanghai 10th People's Hospital Completed No outcome recorded
Also used as a comparator or background therapy in 5 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT05504083 Comparator Sep 2022 → May 2024 InventisBio Co., Ltd Completed No outcome recorded
Phase 2 NCT03185793 Comparator Jul 2017 → Jul 2018 Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT03100318 Comparator Apr 2017 → Apr 2018 gout Fuji Yakuhin Co., Ltd. Completed No outcome recorded
Phase 42 trials
Phase 4 NCT06966635 Background Apr 2024 → Dec 2025 overdue gout, nephrolithiasis Huashan Hospital Recruiting No outcome recorded
Phase 4 NCT03534037 Comparator Feb 2020 → Dec 2021 diastolic heart failure, metabolic syndrome X National Defense Medical Center, Taiwan Unknown No outcome recorded

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as Benzbromarone “Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion...” NCT06966635
10

“ten people with type 2 diabetes received 1 week of empagliflozin, urate transporter 1 blocker benzbromarone, or their combination in a crossover design” PMID 35322793 Mar 2022

NCT02944214

NCT02317861

NCT00422318

NCT02338323

NCT03100318

NCT02790450

NCT05504083

NCT03534037

NCT03185793

Known as Benzbromaron ChEMBL registry synonym — accepted as the source's own label CHEMBL388590
Known as Benzbromarona ChEMBL registry synonym — accepted as the source's own label CHEMBL388590
Known as Benzpromarone ChEMBL registry synonym — accepted as the source's own label CHEMBL388590
Known as Desuric ChEMBL registry synonym — accepted as the source's own label CHEMBL388590
Known as L-2214 ChEMBL registry synonym — accepted as the source's own label CHEMBL388590
Known as MJ 10061 ChEMBL registry synonym — accepted as the source's own label CHEMBL388590
Known as Narcaricin mite ChEMBL registry synonym — accepted as the source's own label CHEMBL388590
Known as NSC-85433 ChEMBL registry synonym — accepted as the source's own label CHEMBL388590
Known as Uroleap ChEMBL registry synonym — accepted as the source's own label CHEMBL388590
Action Inhibit “non-competitive inhibitor of xanthine oxidase” NCT02338323
1

“Solute carrier family 22 member 12 inhibitor” CHEMBL388590

Modality Small molecule CHEMBL388590
Route Oral “take orally, 50mg per day, for 1 year” NCT02338323
Target SLC22A12 “Solute carrier family 22 member 12 inhibitor” CHEMBL388590